Proton pump inhibitors include-

Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole, Pramiprazole, Dextrabeprazole

Refer - Omeprazole

Dexrabeprazole produce a profound increase in drugs whose absorption is pH dependent such as ketoconazole and digoxin. It does not interact with diazepam. thophylline, warfarin or phenytoin.

U.S.FDA  APPROVED DRUGS FROM 01-01-08 TO 31-12-08

U.S.FDA APPROVED DRUGS DURING 2007

Proton pump inhibitors include-

Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole, Pramiprazole, Dextrabeprazole

Refer - Omeprazole

Generally well tolerated.

Most frequently repored adverse events are- Headache, Diarrhoea, and nausea.

In patients patients hypersensitivty to any of the components of the formulation.

Caution to be excercised when it is administerd to patients with severe hepatic dysfunction.

Refer - Omeprazole

Pharmacology

Dexrabeprazole is the R-isomer of racemate rabeprazole, a noval unichiral PPI that was found to be more efective than the racemate and S-rabeprazole. Inhibits gastric acid secretion by inhibiting the H+/K+ -ATPase pump in gastric parietal cells. Dexrabeprazole dissociate more rapidly and completely from H+/K+ - ATPase pump than other PPIs which suggests it may be a revesible inhibitor of the proton pump.

Pharmacokinetics

Dexrabeprazle displays linear pharmacokinrtic profile and well absorbed fromstomach following admin. Food does not alter the rate of extent of bioavailbility of the drug. It is extensively metabolised by CYP2C19 and CYP3A4 enzymes within the liver and 90% of drug excreted in urine as its metabolites.

Food does not alter the rate of extent of bioavailbility of the drug.